#JPMHC24 offered an excellent opportunity to get a glimpse of the entire global healthcare landscape and the upcoming industry trends as Cardior Pharmaceuticals - a Novo Nordisk company is preparing for a new trial evaluating #CDR132L for additional indications.

We are very excited to announce that the European Journal of Heart Failure has just published the article on the rationale and design of the HF-REVERT trial. Congratulations to all the authors and members of the HF-REVERT Team! onlinelibrary.wiley.com/doi/full/10.10…

Cardior's CSO/CMO and Head of Institute for Molecular and Translational Therapeutic Strategies of Hannover Medical School Professor Thomas Thum is taking part in European Society of Cardiology Cardiovascular Round Table in Rome and and will be speaking on miRNAs as therapeutic tools: escardio.org/The-ESC/What-w…

“Long non-coding RNAs in cardiac hypertrophy and heart failure…” by John D. Mably and Da-Zhi Wang in @NaturerevCardiol is a step forward in #noncodingRNAs research and a valuable reference for all scientists in the field. Congrats on the publication! nature.com/articles/s4156…

Happy heart is healthy heart As everybody is posting hearts today, we put up #CDR132L Mode of Action Video on our webpage cardior.de The video explains the mechanism of action of our lead candidate and shows its healing effects on the heart. Happy Valentine❤️❤️

Today we celebrate #women’s achievements but also raise awareness about inequality women face in different domains of life including health: #cardiovascular diseases in women remain understudied, undertreated and women are underrepresented in clinical trials.#InspireInclusion

Dr. Sandor Batkai, Cardior Pharmaceuticals - a Novo Nordisk company's Head of Medical Research and Intelligence will be an expert panelist and will hold a presentation on #microRNA therapeutics in #heartfailure at #Biologics2024. Check the Agenda for details and stop by: oxfordglobal.com/biologics/even…

Tomorrow at 12:37 CET Professor Thomas Thum is speaking on “Clinical development of small #RNA therapeutics” at the 9th German Pharm-Tox Summit in Munich, Germany. The Summit is also held online. More in the program: programme.conventus.de/en/gpts-2024/p…

We are extremely excited to share that Novo Nordisk agreed to acquire Cardior Pharmaceuticals - a Novo Nordisk company for up to €1.025 billion. With Novo, we have found the ideal partner to accelerate the clinical development of lead compound CDR132L which is in Phase 2 in heart failure. bit.ly/3TNAdgI

Huge thanks from the Cardior Pharmaceuticals - a Novo Nordisk company team to all of you, our partners and friends, for your heartfelt congratulations on the potential acquisition by Novo Nordisk. It’s an important step towards bringing #RNA-based therapies to heart failure patients! More cardior.de/media/

On Wednesday April 17 Thomas Thum, Professor of Hannover Medical School and Cardior Pharmaceuticals - a Novo Nordisk company's CSO/CMO is holding a presentation on the development of noncoding #RNA therapeutics for #CDV at Keystone Symposia Cardiovascular Epigenetics and Gene Regulation. Learn more: keystonesymposia.org/conferences/co…

Cardior Pharmaceuticals - a Novo Nordisk company's CEO Dr. Claudia Ulbrich is participating in German Biotech Days 2024 taking place in Berlin on April 16-17. It is the best place to feel the pulse of German biotech and a perfect meeting point for science and business.

As of May 2, 2024 Cardior Pharmaceuticals - a Novo Nordisk company has become a fully owned subsidiary of Novo Nordisk. Happy to combine forces with Novo Nordisk to accelerate the clinical development of our lead compound with the aim of bringing life-saving treatment to heart patients! Two teams in Hannover.

Here’s a teaser to a new episode from Hannover 🇩🇪 with Claudia Ulbrich, CEO and co-founder of Cardior Pharmaceuticals - a Novo Nordisk company. Hear the details about Cardior’s recent €1B exit to Novo Nordisk, miRNA/Cardiovascular and more. Watch on YouTube, Spotify or Apple. What do you think? 🤔

Watch our CEO, Claudia Ulbrich, in the @Flotbio podcast where she discussed the recent €1B acquisition of Cardior by Novo Nordisk . The episode is a deep dive into Cardior Pharmaceuticals - a Novo Nordisk company story and acquisition and the inspiring career of Dr. Claudia Ulbrich: youtube.com/watch?v=yxCw5R…

Cardior’s founder and CSO/CMO Prof. Thomas Thum will present the exciting journey starting from research on #microRNAs at the bench to clinical testing in heart failure and the potential of #CDR132L to tackle the root causes of acute and chronic HF: escardio.org/Congresses-Eve…

Cardior Pharmaceuticals - a Novo Nordisk company CEO Dr. Claudia Ulbrich is participating in demi colton Biotech CEO Summit Europe in Barcelona, Spain on May 27-29, 2024. On Monday May 27 Claudia is invited to speak at Fireside Chat moderated by PKO of Blue Matter. To learn more: biotechceosummit-eu.com/2024-program/

We are happy to announce Thomas Thum and Dr. Claudia Ulbrich are among the finalists of Andreas & Thomas Struengmann Award, the first of its kind in the DACH region aimed at recognizing entrepreneurial achievements in the life sciences arena: businesswire.com/news/home/2024…

We congratulate Vicente Godoy on the promotion to Vice President Quality Management & Compliance and welcome him to Cardior Pharmaceuticals - a Novo Nordisk company Leadership Team!

Dr. Sandor Batkai, Cardior Pharmaceuticals - a Novo Nordisk company's Co-founder & Head of Medical Research and Intelligence, is presenting at the 3rd Annual Heart Failure Drug Discovery & Development Summit in Boston, MA on Aug 1, 2024. Check the agenda for more and stop by: heartfailuresummit.com